Stay updated with breaking news from Shared Instrument Grant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Combining a histone deacetylase inhibitor drug with immunotherapy agents is safe, and may benefit some patients with advanced cancers that have not responded to traditional therapy, according to results of a phase 1 clinical trial led by researchers
Deadline March 30, 2021 Project Description The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated systems. The minimum award is $50,000. There is no maximum price limit for the instrument; however, the maximum award is $600,000. Types of instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron an...